A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

NCT04486352 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

148

Enrollment

OTHER

Sponsor class

Conditions

Endometrial Cancer

Interventions

DRUG: Atezolizumab - 28 Day Cycle
DRUG: Bevacizumab
DRUG: Ipatasertib
DRUG: Talazoparib
DRUG: Trastuzumab emtansine
DRUG: Tiragolumab
DRUG: Atezolizumab - 21 Day Cycle
DRUG: Inavolisib
DRUG: Letrozole
DRUG: Giredestrant
DRUG: Abemaciclib

Sponsor

Alliance Foundation Trials, LLC.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]